ILMN Company Profile and Key Details

Q: Who are the executives of ILMN?

Mr. Charles E. DadswellSenior Vice President, Gen. Counsel & Sec.Ms. Carissa RollinsChief Information OfficerMs. Carissa L. RollinsChief Information OfficerDr. Phillip G. Febbo M.D.Senior Vice President & Chief Medical OfficerMs. Susan H. TousiChief Commercial OfficerMs. Sallilyn SchwartzVice President of Investor RelationsDr. Steven BarnardChief Technology OfficerMr. John FranklinChief Public Affairs OfficerMr. Scott EricksenVice President & Chief Accounting OfficerDr. Joydeep Goswami M.B.A., Ph.D.Chief Financial Officer, Chief Strategy & Corporation Devel. OfficerDr. Alexander Aravanis M.D., Ph.D.Chief Technology Officer & Head of Research and Product Devel.Dr. Phillip G. FebboSenior Vice President & Chief Medical OfficerMr. Kevin Carl PegelsChief of Global OperationsMr. Francis A. deSouzaAdvisorMr. Charles E. Dadswell Esq.Interim Chief Executive Officer & Gen. CounselStephanie CamposPres

NASDAQ : ILMN

Illumina

$141.51

-1.03-0.72%

At Close 4:00 PM

65.22

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Illumina, Inc. (ILMN) stock declined over -0.72%, trading at $141.51 on NASDAQ, down from the previous close of $142.54. The stock opened at $142.54, fluctuating between $140.69 and $144.46 in the recent session.

Stock Snapshot

142.54

Prev. Close

21.41B

Market Cap

140.6901

Day Low

25.73

P/E Ratio

5.5

EPS (TTM)

1.77

Cash Flow per Share

142.54

Open

151.3M

Number of Shares

144.4604

Day High

97.16%

Free Float in %

36.13

Book Value

1.44M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 18, 2026	142.22	144.46	140.69	141.51	1.44M
May 15, 2026	141.46	143.86	138.06	142.54	1.77M
May 14, 2026	149.45	150.20	142.97	143.24	2.01M
May 13, 2026	146.14	148.87	143.21	145.00	2.09M
May 12, 2026	143.50	146.75	142.36	145.70	2.84M
May 11, 2026	140.67	145.21	139.00	142.51	1.94M
May 08, 2026	138.00	142.20	134.67	141.88	1.5M
May 07, 2026	141.37	142.40	137.10	138.71	1.23M
May 06, 2026	139.04	143.01	137.96	142.58	1.33M
May 05, 2026	139.58	142.41	136.36	139.07	1.24M
May 04, 2026	135.45	140.84	133.97	139.37	2.01M
Apr 30, 2026	121.72	128.12	121.43	126.74	2.35M
Apr 29, 2026	125.90	127.44	119.14	120.37	1.74M
Apr 28, 2026	127.97	128.10	125.05	126.92	1.25M
Apr 27, 2026	126.93	129.28	126.93	128.52	1.27M
Apr 23, 2026	128.46	128.67	121.27	125.44	1.51M
Apr 22, 2026	133.22	133.65	129.16	130.50	1.02M
Apr 21, 2026	133.20	137.79	131.01	131.98	1.55M
Apr 20, 2026	134.12	134.49	132.32	132.86	987.62K
Apr 17, 2026	133.47	135.58	130.57	134.50	1.53M

Contact Details

San Diego, CA 92122

United States

https://www.illumina.com 858 202 4500

About Company

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Stock Peers

IDXX

17+3.21%

IDEXX Laboratories, Inc.$545.79 MEDP

5.4+1.30%

Medpace Holdings, Inc.$420.67 NTRA

6.18+3.32%

Natera, Inc.$192.54 ICLR

-2.6-2.23%

ICON Public Limited Company$113.78 EXAS

Exact Sciences Corporation$104.91 GH

0.74+0.78%

Guardant Health, Inc.$95.66 BLLN

3.49+4.22%

BillionToOne, Inc.$86.12 GRAL

1.06+1.78%

GRAIL, Inc.$60.71 RDNT

1.78+3.40%

RadNet, Inc.$54.17 TWST

0.62+1.26%

Twist Bioscience Corporation$49.79

Company Overview

Illumina, Inc. (NASDAQ:ILMN) closed at $141.51 USD, losing -$1.03 (-0.72%) from the previous close of $142.54. The stock is currently mid-range between its 52-week high and low $78.55 and $155.53. With a market capitalization of about $21.41 billion, Illumina, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 1.66 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Illumina, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Jacob Thaysen, the company employs approximately 8,970 people and listed since July 28, 2000. Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.52%, SMA50 -5.71%, SMA200 16.22%). The stock’s 14-day RSI is 49.51 (neutral), while the ATR of 5.04 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -18.09% below its high and over 85.44% above its low. Average 10-day trading volume of 2.01 million shares is slightly above the 3-month average of 1.67 million, indicating heightened recent market interest.

Valuation Metrics

Illumina, Inc. trades at a P/E ratio of 25.39, slightly below the S&P 500 average, with a price-to-sales ratio of 4.88 and a price-to-book ratio of 8.09 trading at moderately above to book value. The P/FCF stands at 21.65, also above market averages.

Dividend & Fair Value

Illumina, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $95.06. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Illumina, Inc. generated EPS of $5.46 over the past year. Five-year average earnings growth is 4.22%. Wall Street analysts project EPS growth of 11.19% annually over the next five years. The latest quarter delivered EPS of $0.88. The next quarter is forecast at $1.06. Next year's EPS is expected at $40.09. Analyst sentiment is neutral. Analyst rating data shows there are 7 Strong Buy ratings, 3 Buy ratings, 15 Hold ratings, 2 Sell rating and 6 Strong Sell ratings. Price targets range from $170.00 to $80.00. The high target offers 20.13% upside. The low target suggests -43.47% downside. The mean target is $124.12. This offers -12.29% upside. Illumina, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -16.19%. The prior quarter beat by 8.87%. Over the last six quarters, Apple has recorded several small beats. These include -6.52% in February 06, 2025.

Shareholding & Insider Activity

Illumina, Inc. has 158.30 million shares outstanding. The public float is 149.35 million shares, elevated short interest at 7.48% of float. This equals 7.73 million shares. The short ratio is 3.43 days. Institutional investors hold 108.15% of the float. Insiders own 0.22%. FLATLEY JAY T holds 148.93 thousand shares, Thaysen Jacob has 82.49 thousand shares and deSouza Francis A has 55.42 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.28 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Illumina generated $4.50B in revenue, or $28.51 per share. Gross margin was 61.06%, operating margin -1.55%, and net profit margin -25.78%. Returns are negative, with ROA at -11.48% and ROE at -20.21%.
On valuation metrics, Illumina trades at a P/E of 25.39, P/S of 4.88 and P/B of 8.09. The current ratio is 1.75 and quick ratio is 1.36. Operationally, the company’s inventory turnover is 2.32 and cash conversion cycle is 162.36 days. Debt-to-equity is 0.92, supported by a cash flow-to-debt ratio of 0.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Illumina posted revenue of $4.50B, down slightly from $4.58B in the prior quarter. Gross profit was $2.75B (margin 61.06%). Operating income was - $70.00M (margin -1.6%). Net income was- $1.16B (EPS - $7.35).
The company ended the quarter with $1.05B in cash and short-term investments, a total debt of $2.26B, and net debt of $1.21B. Total assets were $10.11B, with equity of $5.75B. Financials further reflected stability, with operating cash flow of $477.00M, free cash flow of $281.00M, and capital expenditures of - $196.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Illumina, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.24%, with price expected at $156.00 by June 01, 2026, within a range of $151.51 to $160.38 3-Month Outlook: Projected rise of 43.32%, reaching $202.81 by August 13, 2026, with a range of $199.13 to $206.74. 1-Year Outlook: Projected loss of -11.45%, with price at $125.31 by May 18, 2027, within a range of $114.07 to $134.36.

Key Takeaways

Illumina, Inc. (NASDAQ:ILMN) shares are up 12.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Illumina, Inc. trading at a premium to the broader market with a P/E of 25.39. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $188.36, suggesting 33.11% upside. Our AI forecast model points to short-term strength (10.24% over two weeks), a medium-term rise (43.32% over three months), and a longer-term loss (-11.45% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Illumina, Inc. (ILMN) stock price?

Illumina, Inc. (NASDAQ: ILMN) stock price is $141.51 in the last trading session. During the trading session, ILMN stock reached the peak price of $144.46 while $140.69 was the lowest point it dropped to. The percentage change in ILMN stock occurred in the recent session was -0.72% while the dollar amount for the price change in ILMN stock was - $1.03.

ILMN's industry and sector of operation?

The NASDAQ listed ILMN is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Illumina, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ILMN?

Mr. Charles E. Dadswell
Senior Vice President, Gen. Counsel & Sec.
Ms. Carissa Rollins
Chief Information Officer
Ms. Carissa L. Rollins
Chief Information Officer
Dr. Phillip G. Febbo M.D.
Senior Vice President & Chief Medical Officer
Ms. Susan H. Tousi
Chief Commercial Officer
Ms. Sallilyn Schwartz
Vice President of Investor Relations
Dr. Steven Barnard
Chief Technology Officer
Mr. John Franklin
Chief Public Affairs Officer
Mr. Scott Ericksen
Vice President & Chief Accounting Officer
Dr. Joydeep Goswami M.B.A., Ph.D.
Chief Financial Officer, Chief Strategy & Corporation Devel. Officer
Dr. Alexander Aravanis M.D., Ph.D.
Chief Technology Officer & Head of Research and Product Devel.
Dr. Phillip G. Febbo
Senior Vice President & Chief Medical Officer
Mr. Kevin Carl Pegels
Chief of Global Operations
Mr. Francis A. deSouza
Advisor
Mr. Charles E. Dadswell Esq.
Interim Chief Executive Officer & Gen. Counsel
Stephanie Campos
Pres

How ILMN did perform over past 52-week?

ILMN's closing price is 80.15% higher than its 52-week low of $78.55 where as its distance from 52-week high of $155.53 is -9.01%.

How many employees does ILMN have?

Number of ILMN employees currently stands at 8,970.

Link for ILMN official website?

Official Website of ILMN is: https://www.illumina.com

How do I contact ILMN?

ILMN could be contacted at phone 858 202 4500 and can also be accessed through its website. ILMN operates from 5200 Illumina Way, San Diego, CA 92122, United States.

How many shares of ILMN are traded daily?

ILMN stock volume for the day was 1.44M shares. The average number of ILMN shares traded daily for last 3 months was 1.66M.

What is the market cap of ILMN currently?

The market value of ILMN currently stands at $21.41B with its latest stock price at $141.51 and 151.3M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8970
Beta	1.5
Sales or Revenue	$4.50B
5Y Sales Change%	0.257%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

ILMN Company Profile and Key Details

Illumina

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook